Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

August

27

electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)

Double-blind sham-controlled study of nineteen participants who had experienced trauma but did not have...

24

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

Reimbursement for gammaCore™ in England BASKING RIDGE, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR),...

13

electroCore Announces Second Quarter Financial Results

Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected...

6

ATEC Reports Second Quarter 2020 Financial Results And Recent Corporate Highlights

• U.S. Revenue Grows 11%• Seventh Consecutive Quarter of Year-Over-Year Double-Digit Revenue Increase CARLSBAD, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Alphatec Holdings,...

3

Exagen Inc. Announces a Collaboration with Hospital for Special Surgery (HSS) for Antiphospholipid Syndrome

Proof-of-concept clinical study regarding autoimmune clotting disorder which most commonly increases the risk of...

3

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program

Purchase agreement for up to $250 million in milestone payments plus royalties on future...

30

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Initial distribution to hospitals and patients expected to begin on July 31st BASKING RIDGE,...

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

Paper supports use of nVNS as a front-line therapy for acute and preventative treatment...

28

Exagen Inc. Reports Second Quarter 2020 Results

Testing experiencing monthly sequential improvement; record gross margins of 63% SAN DIEGO, July 28, 2020 (GLOBE...

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting...

17

Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration

Goal to Develop a Novel, Rule-In, Blood Test to Support the Diagnosis of Fibromyalgia...

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living...

Recent developments

News

August

27

electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)

August

24

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

August

13

electroCore Announces Second Quarter Financial Results

August

6

ATEC Reports Second Quarter 2020 Financial Results And Recent Corporate Highlights

August

3

Exagen Inc. Announces a Collaboration with Hospital for Special Surgery (HSS) for Antiphospholipid Syndrome

August

3

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program

July

30

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

July

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

July

28

Exagen Inc. Reports Second Quarter 2020 Results

July

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

June

17

Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration

June

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus